McLauchlan L, Lancaster K, Kearnes M, Mellor R, Ritter A. "It's professional but it's personal": participation, personal connection, and sustained disagreement in drug policy reform. Int J Drug Policy. 2022 Dec;110:103903. doi: 10.1016/j.drugpo.2022.103903
Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, Garcia-Foncillas J, Candrilli S, Kaye JA. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care (Engl). 2020 Mar;29(2):e13213. doi: 10.1111/ecc.13213
La EM, Smyth EN, Talbird SE, Li L, Kaye JA, Lin AB, Bowman L. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom. Eur J Cancer Care (Engl). 2018 Sep;27(5):e12862. doi: 10.1111/ecc.12862
Gourdet C, Giombi KC, Kosa K, Wiley J, Cates S. How four U.S. states are regulating recreational marijuana edibles. Int J Drug Policy. 2017 May;43:83-90. doi: 10.1016/j.drugpo.2017.01.018.
Kosa KM, Giombi KC, Rains CB, Cates SC. Consumer use and understanding of labelling information on edible marijuana products sold for recreational use in the states of Colorado and Washington. Int J Drug Policy. 2017 May;43:57-66. doi: 10.1016/j.drugpo.2017.01.006
Smith VK, Evans MF, Banzhaf HS, Poulos C. Can weak substitution be rehabilitated? Environ Resour Econ (Dordr). 2010 Feb 1;45(2):203-21.
Anderson H, Espinosa E, Lofts F, Meehan M, Hutchinson G, Price N, Heyes AE. Evaluation of the Chemotherapy Patient Monitor: an interactive tool for facilitating communication between patients and oncologists during the cancer consultation. Eur J Cancer Care (Engl). 2001 Jun;10(2):115-23.
Mansfield CA. Despairing over disparities: an empirical analysis of the relationship between willingness-to-pay and willingness-to-accept. Environ Resour Econ (Dordr). 1999;13(2):219-34.